OBJECTIVE--To measure plasma concentrations of noradrenaline and neuropeptide Y-like
immunoreactivity in relation to cardiac function in patients with congestive heart failure …

Neuropeptide Y (NPY) is a peptide released together with noradrenaline (NA) from
sympathetic nerve endings. Elevated plasma levels of NA and NPY‐like immunoreactivity …

Plasma levels of neuropeptide Y‐like immunoreactivity (NPY‐LI) and noradrenaline were
studied for 25 h in 22 patients with acute ischaemic heart disease. On admission, NPY‐LI …

The relationship among neuropeptide Y (NPY), catecholamines and haemodynamics was
assessed both at baseline and during inotropic intervention in patients with congestive heart …

Forty‐two patients with congestive heart failure were studied in order to clarify whether the
plasma level of neuropeptide Y‐like immunoreactivity (NPY‐LI) rises in parallel with plasma …

Abstract purpose: Our objectives were to assess whether plasma neuropeptide Y (NPY)
levels are elevated in patients with congestive heart failure (CHF) and whether or not NPY …

Madsen BK, Husum D., Videbaek R., Stokholm KH, Saslsen L., Christensen NJ Plasma
immunoreactive Neuropeptide Y in congestive heart failure at rest and during exercise …

Neuropeptide Y (NPY) is co-released with noradrenaline from sympathetic nerves, has a
strong vasoconstrictive action, and causes an attenuation of parasympathetic action in …

The myocardial release of neuropeptide Y‐like immunoreactivity (NPY‐LI) and
noradrenaline (NA) during exercise with and without arterial hypoxia was measured in 18 …

Study objective–The aim of the study was to measure plasma neuropeptide Y, which is
related to sympathetic nerve stimulation, in patients admitted to a coronary care unit and to …